A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2

Anhui Provincial Hospital300 enrolled

Overview

To evaluate the efficacy and safety of Pyrotinib Maleate Tablets in the treatment of advanced breast cancer patients with positive her-2.

This study intends to carry out multicenter, observational cohort clinical research, using maleic acid pyrrole for his piece of HER-2 positive treatment of advanced breast cancer treatment, observation and verification maleic acid pyrrole for his piece for a line or a single drug resistance by bead in the real diagnosis and treatment in patients with advanced breast cancer environment and the efficacy and safety of new treatments. Biomarkers of breast cancer prognosis are of great significance in predicting the degree of malignancy, metastasis and recurrence of breast cancer, as well as guiding clinical treatment programs.This study will explore the prognostic factors and curative effect of breast cancer patients from multiple aspects, explore the dominant population of breast cancer patients with pyrrolidone maleate, and provide the theoretical basis for individualized treatment for clinical treatment practice.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

HER2 Positive Breast Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female patients . 2. Confirmed by pathological examination of breast cancer patients with positive her-2 expression 3. The researchers determined that the standard neoadjuvant regimen was ineffective in the treatment of patients with locally advanced her-2 positive breast cancer or that the standard neoadjuvant regimen was not applicable. 4. Patients should be voluntary to the trial and provide with signed informed consent 5. The researchers believe patients can benefit from the study. Exclusion Criteria: 1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Pyrotinib maleate tablets or its accessories 2. Pregnant or lactating women 3. Patients with Pyrotinib maleate tablets contraindications 4. Patients of doctors considered unsuitable for the trial

Outcomes

Primary Outcomes

PFS

Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

Time frame: 1 year

pCR

Pathological complete response is the breast primary focus and axillary lymph node surgery specimen pathological examination without invasive tumor cell residual

Time frame: 1 year

Secondary Outcomes

overall survival is defined as the length of time from random assignment to death or to last contact.

Time frame: 1 year

adverse events are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.

Time frame: 1 year

ORR

Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments

Time frame: 1 year

DCR

Disease control rate (DCR) refers to the percentage of cases with remission and disease stability after treatment in the total number of evaluable cases

Time frame: 1 year

DFS

Disease-free survival (DFS) is defined as the time from the beginning of randomization to recurrence or death due to Disease progression

Time frame: 1 year

DDFS

Central Contacts

Pan Yueyin

CONTACT

13805695536 yueyinpan1965@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.